WO2013003346A3 - Compositions de microarn-31 et leurs procédés d'utilisation dans des maladies auto-immunes - Google Patents

Compositions de microarn-31 et leurs procédés d'utilisation dans des maladies auto-immunes Download PDF

Info

Publication number
WO2013003346A3
WO2013003346A3 PCT/US2012/044197 US2012044197W WO2013003346A3 WO 2013003346 A3 WO2013003346 A3 WO 2013003346A3 US 2012044197 W US2012044197 W US 2012044197W WO 2013003346 A3 WO2013003346 A3 WO 2013003346A3
Authority
WO
WIPO (PCT)
Prior art keywords
microrna
methods
compositions
autoimmune disease
expression
Prior art date
Application number
PCT/US2012/044197
Other languages
English (en)
Other versions
WO2013003346A2 (fr
Inventor
Yihong Yao
Nan Shen
Wei Fan
Yuanjia Tang
Original Assignee
Medimmune, Llc
Shanghai Renji Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune, Llc, Shanghai Renji Hospital filed Critical Medimmune, Llc
Priority to AU2012275552A priority Critical patent/AU2012275552A1/en
Priority to RU2014102217/15A priority patent/RU2014102217A/ru
Priority to BR112013033794A priority patent/BR112013033794A2/pt
Priority to KR1020137035140A priority patent/KR20140066671A/ko
Priority to JP2014518912A priority patent/JP2014521600A/ja
Priority to EP12804592.9A priority patent/EP2723349A4/fr
Priority to CA2841158A priority patent/CA2841158A1/fr
Publication of WO2013003346A2 publication Critical patent/WO2013003346A2/fr
Publication of WO2013003346A3 publication Critical patent/WO2013003346A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Abstract

La présente invention concerne des méthodes de traitement du lupus érythémateux disséminé et d'autres maladies auto-immunes.
PCT/US2012/044197 2011-06-27 2012-06-26 Compositions de microarn-31 et leurs procédés d'utilisation dans des maladies auto-immunes WO2013003346A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2012275552A AU2012275552A1 (en) 2011-06-27 2012-06-26 Microrna-31 compositions and methods for use in autoimmune disease
RU2014102217/15A RU2014102217A (ru) 2011-06-27 2012-06-26 Композиции на основе микрорнк-31 и способы применения при аутоиммунных заболеваниях
BR112013033794A BR112013033794A2 (pt) 2011-06-27 2012-06-26 uso de uma quantidade eficaz de uma composição, e, método para avaliar a presença, ausência ou quantidade de um biomarcador
KR1020137035140A KR20140066671A (ko) 2011-06-27 2012-06-26 자가면역 질환에서 사용되는 마이크로rna-31 조성물 및 방법
JP2014518912A JP2014521600A (ja) 2011-06-27 2012-06-26 マイクロｒｎａ−３１組成物および自己免疫疾患に使用する方法
EP12804592.9A EP2723349A4 (fr) 2011-06-27 2012-06-26 Compositions de microarn-31 et leurs procédés d'utilisation dans des maladies auto-immunes
CA2841158A CA2841158A1 (fr) 2011-06-27 2012-06-26 Compositions de microarn-31 et leurs procedes d'utilisation dans des maladies auto-immunes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161501482P 2011-06-27 2011-06-27
US61/501,482 2011-06-27

Publications (2)

Publication Number Publication Date
WO2013003346A2 WO2013003346A2 (fr) 2013-01-03
WO2013003346A3 true WO2013003346A3 (fr) 2013-02-28

Family

ID=47424764

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/044197 WO2013003346A2 (fr) 2011-06-27 2012-06-26 Compositions de microarn-31 et leurs procédés d'utilisation dans des maladies auto-immunes

Country Status (8)

Country Link
EP (1) EP2723349A4 (fr)
JP (1) JP2014521600A (fr)
KR (1) KR20140066671A (fr)
AU (1) AU2012275552A1 (fr)
BR (1) BR112013033794A2 (fr)
CA (1) CA2841158A1 (fr)
RU (1) RU2014102217A (fr)
WO (1) WO2013003346A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112843233A (zh) * 2019-11-26 2021-05-28 中国科学院上海营养与健康研究所 预防皮肤衰老与早衰的内源性小rna分子标靶及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070744A1 (fr) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Inhibition induite par interference arn de l'expression du gene de l'interleukine au moyen d'acides nucleiques interferents courts (sina)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101376910B (zh) * 2007-08-27 2012-01-11 中国科学院上海生命科学研究院 微小rna基因在系统性红斑狼疮疾病诊断和治疗中的作用
JP2012511031A (ja) * 2008-12-05 2012-05-17 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ｍｉＲ−３１に関連する組成物および方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070744A1 (fr) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Inhibition induite par interference arn de l'expression du gene de l'interleukine au moyen d'acides nucleiques interferents courts (sina)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CRISPIN ET AL.: "Novel molecular targets in the treatment of systemic lupus erythematosus", AUTOIMMUN. REV., vol. 7, no. 3, January 2008 (2008-01-01), pages 256 - 261, XP022413409 *
CRISPIN ET AL.: "Transcriptional regulation of IL-2 in health and autoimmunity''''.", AUTOIMMUN. REV., vol. 8, no. 3, January 2009 (2009-01-01), pages 190 - 195, XP025769802 *
MOK ET AL.: "Pathogenesis of systemic lupus erythematosus", J. CLIN. PATHOL., vol. 56, no. 7, July 2003 (2003-07-01), pages 481 - 90, XP055140771 *
See also references of EP2723349A4 *

Also Published As

Publication number Publication date
KR20140066671A (ko) 2014-06-02
BR112013033794A2 (pt) 2019-09-24
AU2012275552A1 (en) 2014-02-06
JP2014521600A (ja) 2014-08-28
EP2723349A4 (fr) 2015-01-14
EP2723349A2 (fr) 2014-04-30
WO2013003346A2 (fr) 2013-01-03
CA2841158A1 (fr) 2013-01-03
RU2014102217A (ru) 2015-08-10

Similar Documents

Publication Publication Date Title
WO2014113089A3 (fr) Polynucléotides capteurs de signal servant à modifier les phénotypes cellulaires
WO2012159051A3 (fr) Graphène chimiquement modifié
WO2014153470A3 (fr) Interruption ciblée de gènes de récepteur des lymphocytes t à l'aide de nucléases protéiques à doigt de zinc génétiquement modifiées
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX2016008448A (es) Conjugados de var2csa-farmaco.
WO2014144978A8 (fr) Compositions améliorées pour le traitement de la dystrophie musculaire
EP4036240A3 (fr) Tampon de transduction
PH12016501414A1 (en) Long-acting insulin and use thereof
PH12014501108A1 (en) Anti-il-36r antibodies
WO2012177444A3 (fr) Co-agonistes du récepteur du glucagon et du récepteur du gpl-1
EP2970909A4 (fr) Procédés et compositions associés à l'activité des lymphocytes t
WO2012177443A3 (fr) Co-agonistes du récepteur du glucagon et du récepteur du gpl-1
MD20150091A2 (ro) Compuşi antivirali
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
EP2863910A4 (fr) Compositions et procédés pour réguler l'homéostasie du glucose et l'action de l'insuline
WO2013022991A3 (fr) Méthodes et compositions associées à p62 pour le traitement et la prophylaxie du cancer
WO2014086982A3 (fr) Composés métalliques stables, leurs compositions et procédés d'utilisation
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
GB2489382A (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
EP3452494A4 (fr) Compositions et procédés associés à des immunogènes du vih-1
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
EP3273952A4 (fr) Procédés et compositions pour inhiber les symptômes associés à la veisalgie
MX367393B (es) Composiciones antifungicas para el tratamiento de piel y uñas.
EP3423472A4 (fr) Compositions comprenant des enveloppes de vih pour induire des anticorps de lignée ch235
EP3146494A4 (fr) Utilisation de structure de contenu pour connecter socialement des utilisateurs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12804592

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/014859

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2841158

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2014518912

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20137035140

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012804592

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014102217

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2012275552

Country of ref document: AU

Date of ref document: 20120626

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013033794

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013033794

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20131227